Sugi Predict

Sugi Predict / Compounds / SCHEMBL20147633

SCHEMBL20147633

SCHEMBL20147633

COc1cc(OC)nc(C(=O)NC2(C)CCN(C(C)C)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 1/20 0.42
▸ RET P07949 2/20 0.40
▸ MMP1 P03956 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ CTSA P10619 1/20 0.36
▸ CYP1A2 P05177 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ SLC5A7 Q9GZV3 2/20 0.33
▸ HCN1 O60741 1/20 0.33
▸ HCN4 Q9Y3Q4 1/20 0.33
▸ F10 P00742 1/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20148063 0.90 MCHR1 (0.41) MCHR1RETCTSACYP1A2NTRK1
SCHEMBL20147638 0.86 RET (0.43) MCHR1RETMMP1MMP9MMP13
SCHEMBL20070353 0.86 RET (0.42) MCHR1RETMMP1MMP9MMP13
SCHEMBL20147629 0.84 RET (0.37) MCHR1RETMMP1MMP9MMP13
SCHEMBL21651995 0.84 MCHR1 (0.45) MCHR1RETMMP1MMP9MMP13
SCHEMBL20147645 0.80 HRH3 (0.43) MCHR1RETMMP1MMP9MMP13
SCHEMBL20147622 0.78 MCHR1 (0.42) MCHR1RETMMP1MMP9MMP13
SCHEMBL20147630 0.78 RET (0.44) MCHR1RETMMP1MMP9MMP13
SCHEMBL20147641 0.78 P2RX7 (0.38) MCHR1RETMMP1MMP9MMP13
SCHEMBL20147605 0.77 EGLN1 (0.45) MCHR1RETHRH3EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 — — US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 — — US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 — — US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MCHR1 1063/4885RET 1/4885MMP1 3562/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 MCHR1 1063/4885RET 1/4885MMP1 3562/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 MCHR1 1063/4885RET 1/4885MMP1 3562/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MCHR1 1063/4885RET 1/4885MMP1 3562/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MCHR1 1063/4885RET 1/4885MMP1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.